Drug Trial Radar · NCT05221398
Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10,000
Planned (sponsor's estimate)
Start
Mar 3, 2019
Primary completion
Dec 18, 2030
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Guangxi Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 3, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Though hepatectomy is one of the curative treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC. However, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy was reported.
Conditions
- Hepatocellular Carcinoma
Interventions
Immune Checkpoint Inhibitors Based Adjuvant therapyDrug
Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy
Active surveillanceOther
Patients in this group only receive active surveillance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-free survivialTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jian-Hong Zhong
Nanning, Guangxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.